Tag Archives: BMY stock research
Bristol-Myers Squibb (BMY) 24Q4 Update
24Q4 net revenue rose 7.5% to $12.3 billion, with gains in Eliquis and the growth portfolio more than offsetting LOE-related declines in Revlimid, Pomalyst, Sprycel and Abraxane. Growth portfolio net revenues rose 9.5% sequentially and 29% YOY. Gross margin fell … Continue reading